Adrenomedullin
Cerebral Arteriopathy, Autosomal Dominant, With Subcortical Infarcts And Leukoencephalopathy, Type 1
Explore 5 assets in Cerebral Arteriopathy, Autosomal Dominant, With Subcortical Infarcts And Leukoencephalopathy, Type 1 →Floatz Rating
B57/100
Confidence
Indicative
Sponsor
National Cerebral and Cardiovascular Center, Japan
Modality
protein_peptide
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
42Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06072118CT.gov Adrenomedullin for CADASIL | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Cerebral Arteriopathy, Autosomal Dominant, With Subcortical Infarcts And Leukoencephalopathy, Type 1
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Adrenomedullin (this asset) | National Cerebral and Cardiovascular Center, Japan | P2 | B · 57 |
| Hov-12020 | Hovid Berhad | P2 | B |
| Dabigatran | S. Andrea Hospital | P2 | CCC |
| Physiologic Sodium Chloride Solution | Ever Neuro Pharma GmbH | P2 | CCC |
| Fremanezumab | Mayo Clinic | P2 | CCC |
| Cerebrolysin | Ever Neuro Pharma GmbH | P2 | CCC |
| Cilostazol | Mayo Clinic | P1/2 | CCC |
Other indications for Adrenomedullin
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Migraine Disorder | — | N/A | D · 30 |
| Brain Disorder | — | N/A | D · 30 |
| Central Nervous System Disorder | — | N/A | D · 30 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Adrenomedullin in Cerebral Arteriopathy, Autosomal Dominant, With Subcortical Infarcts And Leukoencephalopathy, Type 1. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/adrenomedullin-cerebral-arteriopathy-autosomal-dominant-with-subcortical-infarcts-and-leukoencephalopathy-type-1
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →